Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Cabaletta Bio, Inc. reported preliminary financial results for the three months ended March 31, 2026.
- Period
- the three months ended March 31, 2026
- Result
- preliminary results
Exact text from the filing
As of March 31, 2026, the Company had approximately $117 million in cash and cash equivalents. This preliminary financial information is subject to completion, and is the responsibility of management and has been prepared in good faith on a consistent basis with prior periods. However, the Company has not reported its financial results for the three months ended March 31, 2026, and its actual results could be materially different from this preliminary financial information.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Cabaletta Bio, Inc. entered into Underwriting Agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. valued at $2.90 per share (effective 2026-05-04).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co.
- Value
- $2.90 per share
- Effective
- 2026-05-04
Exact text from the filing
On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).
View on SEC.gov